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The myeloperoxidase (MPO) and neutrophil elastase genes are expressed specifically in immature myeloid
cells. The integrity of a polyomavirus enhancer core sequence, 5'-AACCACA-3', is critical to the activity of the
murine MPO proximal enhancer. This element binds two species, myeloid nuclear factors lot and 1p (MyNF1ao
and
-P), present in 32D c13 myeloid cell nuclear extracts. The levels of the MyNFls increase during early 32D
c13 cell granulocytic differentiation. Both MyNF1a and -I supershift with an antiserum raised by using a
peptide derived from the N terminus of polyomavirus enhancer-binding protein 2/core-binding factor
(PEBP2/CBF) a subunit. The specific peptide inhibits these supershifts. In vitro-translated PEBP2/CBF
DNA-binding domain binds the murine MPO PEBP2/CBF site. An alternate PEBP2/CBF consensus site,
5'-GACCGCA-3', but not a simian virus 40 enhancer core sequence, 5'-TTCCACA-3', binds the MyNFls in
vitro and activates a minimal murine MPO-thymidine kinase promoter in vivo. The murine neutrophil elastase
gene 100-bp 5'-flanking sequences contain several functional elements, including potential binding sites for
PU.1, C/EBP, c-Myb, and PEBP2/CBF. The functional element 5'-GGCCACA-3' located at positions -66 to 72
differs from the PEBP2/CBF consensus (5'-PuACCPuCA-3') only by an A-to-G transition at position 2. This
DNA element binds MyNFla and -j weakly. The N terminis of two PEBP2/CBF a subunit family members,
PEBP2aA and PEBP2aiB (murine AMLU), are nearly identical, and 32D c13 cells contain both corresponding
mRNAs. Since t(8;21), t(3;21), and inv(16), associated with myeloid leukemias, disrupt subunits of PEBP2/
CBF, we speculate that the resulting oncoproteins, AML1-ETO, AMLl-EAP, AMLl-Evil, and CBFNI-MYH11,
inhibit early myeloid differentiation.
Myeloid cells, which consist of granulocytes, monocytes, and
their precursors, account for approximately half of the hema-
topoietic cells in human and murine marrow. To identify the
transcriptional events which initiate myeloid differentiation, we
are investigating the regulation of genes expressed in immature
myeloid cells. Myeloperoxidase (MPO) and neutrophil elastase
(NE) are microbicidal proteins present in the primary granules
of myeloid cells (32, 48). These proteins, and their cognate
mRNAs, are not found in other cell lineages (48, 51), and
transcriptional regulation is in part responsible for their lin-
eage-specific expression (15, 39, 62). MPO and NE are early
markers of both the granulocytic and monocytic lineages (14,
38). Human MPO protein has been detected even in myeloid
progenitor cells (46).
The murine and human MPO genes have been cloned and
sequenced (17, 55). They both lack a TATAA homology. The
murine MPO gene initiates transcription from two major sites
separated by approximately 400 bp (15). The sequences be-
tween, and those 1,200 bp upstream of, these sites are 60%
homologous to the region of the human MPO gene located
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upstream of its major initiation site (17, 55). Functional
analysis of the murine MPO 5'-flanking region delimited a
414-bp myeloid enhancer located just upstream of the murine
MPO initiation sites (47). The homologous region of the
human MPO gene contains a DNase I-hypersensitive site (19,
25). This enhancer contains several functional elements, in-
cluding a potential Myb-binding site (47). Mutation of a
centrally located enhancer core motif, 5'-AACCACA-3',
markedly diminished the activity of the murine MPO en-
hancer, and this DNA element was found to bind a set of
myeloid-restricted nuclear factors termed MyNFls (47).
We have now found that the MyNFls are members of the
recently described polyomavirus enhancer-binding factor
2/core-binding factor (PEBP2/CBF) family of transcriptional
activators. We also demonstrate that a PEBP2/CBF will bind
and regulate the murine NE gene and that the murine NE
enhancer contains additional functional elements, including
potential binding sites for a C/EBP, PU.1 or another Ets family
member, and Myb.
PEBP2/CBFs were first purified on the basis of their ability
to bind the core sites of polyomavirus or Moloney murine
leukemia virus (20, 56). Two core-binding species, PEBP2A
and PEBP2B, were detected by mobility shift assays (42).
These two factors contain a common I subunit and different ax
subunits. The cDNAs encoding the murine ot subunits,
PEBP2uA and PEBP2otB, have been cloned (4, 36), as has the
cDNA encoding the murine 3 subunit, PEBP2p/CBFP3 (35,
56). PEBP2p/CBFP does not bind DNA directly but strength-
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ens the affinity of a subunits for DNA (35, 57). Alternatively
spliced forms of each of the aL subunits and of the L subunit
have been detected (4, 35, 36, 57).
The PEBP2cx subunits each contain a region homologous to
the Drosophila Runt protein (21). This 127-amino-acid Runt
homology domain is required for DNA binding and het-
erodimerization (26, 36). The consensus DNA-binding site for
PEBP2atA is 5'-PuACCPuCA-3' (20), and the consensus
DNA-binding site for PEBP2aB is 5'-ACCPuCA-3' (26). The
a subunits will not bind the related DNA element 5'-1TC
CACA-3', which is found at the core of the simian virus 40
enhancer and interacts with C/EBPs, AP-3, and TEF-2 (9, 18,
30).
The human PEBP2cxB gene, also termed the AML1 gene, is
located at the breakpoint of t(8;21)(q22;q22), which is associ-
ated with some cases of FAB M2 acute myeloid leukemia (29).
These leukemic cells produces a fusion transcript, AMLl-ETO
(12, 28). The AML1 gene is also involved in t(3;21)(q26;q22),
which is associated with some cases of therapy-associated
myeloid leukemia and chronic myeloid leukemia blast crisis,
and produces an AMLI-EAP (34) or AMLl-Evil (27) fusion
gene. Finally, the human PEBP20/CBFP gene is fused to a
smooth muscle myosin gene as a result of inv(16)(pl3q22),
which is associated with FAB M4eo cases of acute myeloid
leukemia (24). Our findings suggest that some or all of the
oncoproteins expressed as a result of these chromosomal
abnormalities could impair myeloid differentiation through
inhibition of PEBP2/CBF function in leukemic cells.
MATERIALS AND METHODS
Cells and transfection. 32D c13 cells (53) were maintained at
37°C in a 5% CO2-Iscove modified Dulbecco medium supple-
mented with 10% heat-inactivated fetal bovine serum and 5%
WEHI-3B supernatant as a source of interleukin 3 (58). For
induction of granulocytic differentiation, cells were washed
twice with phosphate-buffered saline (PBS) and placed in
Iscove modified Dulbecco medium-10% heat-inactivated fetal
bovine serum supplemented with 1,000 U of granulocyte
colony-stimulating factor (G-CSF) (Amgen) per ml. Mouse L
cells (22) were maintained in Dulbecco modified Eagle medi-
um-10% fetal bovine serum.
Transient transfection of 32D c13 cells and L cells, luciferase
assay, and chloramphenicol acetyltransferase (CAT) assay
were accomplished as described previously (47).
Nuclear extracts with DFP. Nuclear extracts were prepared
by the method of Dignam et al. (11) as modified by Lee et al.
(23). Cells (2 x 108) were washed twice with PBS and
incubated on ice in 5 ml of buffer A containing 5 mM
diisopropylfluorophosphate (DFP) (Sigma) for 15 min. The
cells were then resuspended in 2 of ml buffer A-0.5 mM
DFP-0.75% nonfat dried milk (Carnation)-0.01% Nonidet
P-40-0.5 mM dithiothreitol-0.4 mM phenylmethylsulfonyl flu-
oride-2 mM benzamidine-0.5 mM spermidine-10 ,ug of leu-
peptin per ml-1 ,ug of pepstatin A per ml-1 ,ug of antipain per
ml-1 ,ug of chymostatin per ml-2 ,ug of soybean trypsin
inhibitor per ml-10 jig of aprotinin per ml. Cells were then
lysed by 10 passes of a Dounce homogenizer. Nuclei were
pelleted at 850 x g for 5 min, washed similarly with the same
solution lacking DFP, resuspended in 1 ml of this solution, and
microcentrifuged at 16,000 x g for 5 min. Nuclei were then
lysed by addition of 0.6 ml of buffer C containing dithiothreitol,
phenylmethylsulfonyl fluoride, benzamidine, spermidine, and
the peptide protease inhibitors listed above. After being
rocked at 4°C for 30 min, the extracts were microcentrifuged,
and the supernatants were aliquoted, quickly frozen in liquid
nitrogen, and stored at -70°C. Analysis by the Bradford assay
(Bio-Rad) showed that these extracts contained 2 to 2.5 mg of
protein per ml.
EMSA. Nuclear extracts (6 to 8 jig) were preincubated at
4°C for 5 min in a volume of 20 jil with 2 jig of dIdC-0.1 mg
of bovine serum albumin per ml-50 mM KCl-70 mM NaCl-10
mM Tris (pH 7.5)-i mM dithiothreitol-0.5 mM EDTA-1 mM
phenylmethylsulfonyl fluoride-10% glycerol. When desired,
unlabelled competitor oligonucleotides (10 to 200 ng) were
included in this 5-min preincubation. For supershift assays, 1 to
2 ,ul of either anti-PEBP2/CBF a subunit antiserum (26) or
normal rabbit serum was then added, in the presence or
absence either of 4 jig of PEBP2/CBF at subunit N-terminal
peptide or of an internal PU.1 peptide, and incubation was
continued for 30 min on ice. One nanogram of oligonucleotide,
radiolabelled and blunted by Klenow fragment fill-in, was then
added, and incubation was continued on ice for 30 min. In vitro
transcription and translation in reticulocyte lysates of the
PEBP2aB Runt homology domain was carried out as de-
scribed previously (26); 1 jil was used similarly for electro-
phoretic mobility shift assay (EMSA). The mixtures were then
resolved on a 5% acrylamide gel run at 20 mA at 4°C for 3 h
in 0.33 x Tris-borate-EDTA. The resulting gel was then dried
and exposed to Kodak XAR film.
Isolation of the murine NE promoter. The human NE
cDNA (48) was used to screen a murine BALB/c genomic
library (provided by T. Lanahan) at high stringency (40). A
single lambda plaque was rescreened twice and contained a
19-kb insert. This insert was restriction mapped and subcloned.
Subclones containing exons were identified by Southern blot-
ting with human NE probe. These exons and adjacent DNA
segments were sequenced by the dideoxy chain termination
method (41), and the first exon and upstream promoter
sequences were identified by homology with the human NE
gene (49).
Plasmid construction and oligonucleotides. A modified pBS
(Stratagene) was created in which a BglII and NcoI site had
been placed between the polylinker HindIlI and Sall sites by
using annealed oligonucleotides. A 1.8-kb BamHI-NcoI mu-
rine NE genomic subclone was ligated into this plasmid after it
was digested with BglII-NcoI. The NcoI site encodes the first
translated ATG in murine NE. The NcoI site was then
eliminated by using mung bean nuclease, and then a 1.8-kb
HindIIIISalI fragment containing 1,800 bp of murine NE
5'-flanking sequences, including the 5'-untranslated se-
quences, was ligated into similarly digested p19LUC (54) to
created pNELUC. Clustered point mutations were introduced
into pNELUC by oligonucleotide-mediated mutagenesis (45),
replacing bases -47 to -42 with 5'-CTCGAG-3', -61 to -55
with 5'-CTCGAGG-3', -69 to -66 with 5'-CTCG-3', -85 to
-79 with 5'-CTCGAGC-3', -95 to -91 with 5'-TCGAG-3',
and -107 to -103 with 5'-TCGAG-3', thereby creating XhoI
sites at each location. TATAA is numbered -31 to -27, as in
human NE. A 5' deletion series was created by treating
plasmids containing clustered point mutations with HindIll,
XhoI, and Klenow enzyme, after which the resulting larger
fragments were religated.
Oligonucleotides containing the wild-type murine MPO
MyNF1 site (5'-AACCACA-3') and mutant MyNF1 site (5'-
TAGCACA-3') have been described previously (47). An oli-
gonucleotide in which the wild-type MyNF1 site is replaced
with 5'-GACCGCA-3', which fits the PEBP2/CBF consensus,
was obtained by annealing 5'-CTAGACTGACCATTGAC
CGCAACCAGTTG-3' with 5'-CTAGCAACTGGTTGCG
GTCAATGGTCAGT-3'. An oligonucleotide in which the
wild-type MyNF1 site is replaced with 5'-TTCCACA-3', the
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simian virus 40 enhancer core site, was obtained by annealing
5'-CTAGACTGACCAThllTCCACAACCAGTTlG-3' with 5'-
CTAGCAACTGG1TGTGGAAAATGGTCAGT-3'. These oli-
gonucleotides were each ligated into NheI-digested pM-
POH(zA-552/-241)TKLUC, and the single copy and forward
orientation of inserted oligonucleotides were confirmed by Hin-
dIII-NheI digestion of the resulting plasmids.
An oligonucleotide containing the wild-type murine NE
MyNF1 site was obtained by annealing 5'-TCGACAGT
AGGGCTGTGGCCAGGATGGGG-3' with 5'-TCGACCC
CATCCTGGCCACAGCCCTACTG-3'. A similar oligonucle-
otide containing a mutant MyNF1 site was obtained by anneal-
ing 5'-TCGACAGTAGGGCCGAGACCAGGATGGGG-3'
with 5'-TCGACCCCATCCTGGTCTCGGCCCTACTG-3' or
by annealing 5'-TCGACAGTAGGGCTGTCTCGAGGAT
GGGG-3' with 5'-TCGACCCCATCCTCGAGACAGCCC
TACTG-3'. A similar oligonucleotide containing a murine
MPO-type MyNF1 site in place of the murine NE site was
obtained by annealing 5'-TCGACAGTAGGGCTGTGGTTA
GGATGGGG-3' with 5'-TCGACCCCATCCTAACCACAG
CCCTACTG-3'. The USF oligonucleotide has been described
previously (47).
The PEBP2ocB Runt homology domain (amino acids 50 to
177) was transferred to pBS (Stratagene) by PCR.
RNA preparation and Northern (RNA) blotting. Total cel-
lular RNA was prepared by the acid phenol-guanidinium
isothiocyanate procedure (8). Poly(A)+ mRNA was obtained
by single selection on an oligo(dT)-cellulose (Bethesda Re-
search Laboratories) column as described previously (40). For
Northern blotting, 20 jig of total mRNA or 5 pLg of poly(A)+
mRNA was resolved on a 1% agarose-formaldehyde gel and
transferred (40) to a nylon membrane (GeneScreen; New
England Nuclear). Filters were prehybridized and hybridized
at 42°C in 50% formamide-6X SSC (1 x SSC is 0.15 M NaCl
plus 0.015 M sodium citrate)-2x Denhardt's solution-0.1%
sodium dodecyl sulfate (SDS)-100 pLg of sonicated, boiled
salmon testis DNA per ml. Probes were radiolabelled with 32P
by random priming (13). Filters were washed to a stringency of
65°C in 0.1X SSC-0.05% SDS for 30 min and exposed to
autoradiography film at -70°C. The murine P5-tubulin probe
has been described previously (15). Murine NE mRNA was
detected by using a 400-bp genomic probe containing murine
NE exon 4. A 1.8-kb EcoRI fragment containing the murine
PEBP2otB cDNA (4) and a 2.5-kb EcoRI fragment containing
most of the murine PEBP2otA cDNA (36) were used as probes
as well.
Nucleotide sequence accession number. The GenBank ac-
cession number for murine NE is U04962.
RESULTS
The MyNFls are intact in DFP nuclear extracts. We had
previously found that the ubiquitious transcription factor USF
was intact in uninduced 32D c13 or L-cell extracts prepared
without DFP. However, USF was completely degraded in
4-day-induced 32D c13 extracts prepared similarly (47), likely
because of abundant proteases in their primary granules. To
improve protein integrity, we introduced three modifications
into our nuclear extraction procedure. First, intact cells were
incubated with DFP, a very strong covalent serine protease
inhibitor which can traverse cell membranes (60). DFP was
also included in the cell lysis buffer. Second, nonfat dried milk
was included in the cell lysis buffer as a protease "sink" (10).
Third, extracts were frozen without dialysis. Extracts from
uninduced 32D c13 cells and from 32D c13 induced to the
promyelocytic stage of granulocyte differentiation by exposure
t 0
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FIG. 1. Integrity of MyNFIs and USF in 32D c13 cell DFP nuclear
extracts. Nuclear extracts were prepared from uninduced (32D-IL3)
and 4-day-induced (32D-G4) 32D c13 cells as described previously (47)
with the following modifications: cells were treated with 5 mM DFP
prior to lysis, 0.5 mM DFP and 0.75% nonfat dried milk were included
in the cell lysis buffer, and extracts were not dialyzed. The integrity of
the MyNFIs and of USF in these extracts and in an L-cell extract
produced as described previously (47) was assessed by EMSA.
to G-CSF for 4 days (53) were prepared in this manner. The
integrity of USF and of the MyNFls in these extracts and in an
L-cell nuclear extract prepared without these modifications
was determined by EMSA (Fig. 1). USF was intact in the L-cell
and uninduced 32D c13 cell extracts and was approximately
60% intact in the induced 32D c13 cell extract. The MyNFly
species previously noted in induced 32D c13 extracts (47) was
no longer observed. Instead, now both MyNFlo and MyNF1l
levels increased during early 32D c13 cell differentiation,
whereas previously only MyNF13 had been noted to increase
(47). Thus, MyNFlo was not degraded to MyNFly in DFP
nuclear extracts.
The MyNFI-binding site fits the PEBP2/CBF consensus.
The MyNFl-binding site fits the viral enhancer core motif
5'-(T/A)(T/A)(T/A)CCACA-3' present in a variety of mam-
malian viruses (59). One group of enhancer core-binding
proteins, typified by the C/EBPs, prefers the site 5'-TTC
CACA-3' (1, 18). However, a C/EBP oligonucleotide did not
compete for MyNF1 binding (47). Also, the murine MPO
MyNFl-binding site is 5'-AACCACA-3', which better fits the
consensus for the PEBP2/CBF family, 5'-PuACCPuCA-3'. To
further test the hypothesis that the MyNFls are PEBP2/CBFs,
we prepared a murine MPO-derived oligonucleotide in which
the centrally located MyNFI-binding site had been changed to
5'-GACCGCA-3', which still conforms to the PEBP2/CBF
consensus. We also prepared a similar oligonucleotide in which
the MyNFl-binding site had been changed to 5'-TTCCACA-
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FIG. 2. Characterization of the murine MPO MyNFl-binding site in vitro and in vivo. (a) Four murine MPO-derived, 33-bp oligonucleotides
were radiolabelled to similar specific activities and used in an EMSA with 6 ,ug of 4-day-induced 32D c13 cell DFP nuclear extracts. The centrally
located MyNFl-binding site either was wild type (AACCACA), was a previously described down-mutant (47) (TAGCACA), fit the PEBP2/CBF
consensus (20) (GACCGCA), or matched the simian virus 40 enhancer core (62) (TTCCACA). The positions of MyNFla and MyNF1B are
indicated. (b) The wild-type murine MPO oligonucleotide was radiolabelled and incubated with similar extracts either in the absence of competitor
(NC) or in the presence of either a 10-, 50-, or 200-fold excess of each of the four, unlabelled, oligonucleotides described for panel a. (c) A single
copy of each of these four oligonucleotides was ligated upstream of base -241 in pMPOH(A-552/-241)TKLUC. The activities of the resulting
four MPO-TK derivatives and of the initial construct in induced 32D cl3 cells were determined by transient transfection. The average fold increase
in activity from the insertion of each oligonucleotide, from four experiments, is shown.
3', fitting the C/EBP consensus. These two oligonucleotides,
the wild-type oligonucleotide, and a mutant oligonucleotide
with site 5'-TAGCACA-3' were labelled to similar specific
activities and used in an EMSA with extracts from 4-day-
induced 32D c13 cells (Fig. 2a). Only the oligonucleotides
containing enhancer core sites fitting the PEBP2/CBF consen-
sus bound MyNFla and MyNFl,. To confirm these differ-
ences in affinity, an EMSA competition experiment was per-
formed (Fig. 2b). The ability of a 10-, 50-, or 200-fold excess of
each unlabelled oligonucleotide to compete for MyNF1 bind-
ing to 1 ng of radiolabelled wild-type murine MPO oligonu-
cleotide was determined. A 10-fold excess of the two oligonu-
cleotides with DNA elements which fit the PEBP2/CBF
consensus prevented binding almost completely, whereas even
a 50-fold excess of the other two oligonucleotides only per-
turbed binding mildly.
These assays show that the MyNFls bind in vitro to sites
which fit the PEBP2/CBF consensus. To determine whether
the MyNFls bind and function through the same sites in vivo,
each of the four oligonucleotides employed for Fig. 2 was
assessed for its ability to stimulate a minimal MPO-thymidine
kinase (TK) promoter in induced 32D c13 cells. A single copy
of each oligonucleotide was inserted in the forward orientation
upstream of base -241 in pMPOH(A-552/-241)TKLUC.
This plasmid lacks the MyNFl-binding site and several sur-
rounding elements that are active only in myeloid cells. It
retains an element located between positions -71 and 0 which
was equally active in 32D c13 cells and L cells (47) and also
contains a TATAA homology in the TK segment. We em-
ployed this method because the wild-type murine MPO oligo-
nucleotide, containing an MyNFl-binding site, stimulated
pMPOH(A-552/-241)TKLUC 30-fold but stimulated
pTKLUC only 4-fold (47). Apparently, the MyNFls are opti-
mally active in cooperation with additional factors. Also, in
32D c13 cells the activity of pTKLUC was often near the limits
of detection, whereas pMPOH(A-552/-241)TKLUC was
ninefold more active (47). We found that the two oligonucle-
otides containing sites which fit the PEBP2/CBF consensus
consistently increased the activity of pMPOH(A-552/
-241)TKLUC 20- to 40-fold, whereas the other two oligonu-
cleotides were not stimulatory (Fig. 2c). Of note, the 5'-
GACCGCA-3' site was about twice as active in vivo as the
5'-AACCACA-3' site and bound the MyNFis with about twice
the affinity in vitro as well (Fig. 2a).
To verify that PEBP2/CBF can bind the wild-type murine
MPO-derived oligonucleotide, the ability of an in vitro-tran-
scribed and -translated Runt homology domain derived from
PEBP2atB to bind this oligonucleotide was assessed (Fig. 3a).
Specific binding at the PEBP2/CBF site was observed.
The MyNFls supershift with PEBP2/CBF a subunit anti-
serum. The oligonucleotide containing a centrally located
murine MPO MyNFl-binding site was radiolabelled and incu-
bated with extracts from 4-day-induced 32D c13 cells. For
supershift assay, the extracts were preincubated for 30 min
with 1 or 2 [il of a rabbit polyclonal antiserum raised against a
17-amino-acid peptide derived from the N terminus of
PEBP2acB coupled to keyhole limpet hemocyanin (26). To
block the antiserum, 4 jig of the specific peptide was added to
the extract prior to antiserum addition (Fig. 3b). Inclusion of
the PEBP2atB antiserum disrupted or shifted the MyNF1p
species completely, and 60 to 80% of the MyNFla species
were disrupted or shifted as well. A doublet, likely containing
supershifted MyNFla and MyNFl1, was evident near the top
of the lanes in which antiserum, but no peptide, was added.
This doublet is better seen in Fig. 3c and in Fig. 7c, lane 5. A
specific peptide, but not a nonspecific peptide derived from
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FIG. 3. The murine MPO MyNFI-binding site binds PEBP2/CBF. (a) Binding by in vitro-transcribed and -translated PEBP2/CBF. The
DNA-binding Runt homology domain (rhd) of PEBP2ztB was transcribed and translated as described previously (26). The ability of this protein
to bind the murine MPO PEBP2/CBF site was compared with that of an induced 32D c13 extract in the absence of specific competitor (32D and
ivt), in the presence of a 50-fold excess of wild-type competitor (32D+WC and ivt+WC), or in the presence of a 50-fold excess of mutant
competitor (32D+MC and ivt+MC). (b) Supershift assay using the murine MPO MyNFI site and PEBP2/CBF antiserum. The murine MPO
oligonucleotide was radiolabelled, incubated with 6 p.g of 4-day-induced 32D c13 cell DFP nuclear extracts, and analyzed by EMSA (32D). The
ability of an antiserum raised against the N terminus of the ox subunit of PEBP2/CBF to disrupt or supershift the MyNFI species was assessed by
adding 1 or 2 RIX of anti-PEBP2/CBF antiserum to the nuclear extracts prior to probe addition (32D+Ab). The specificity of the antiserum-MyNFI
interaction was assessed by addition of 4 ,ug of the specific peptide to the nuclear extracts prior to antiserum addition (32D+Ab+pep). The
positions of supershifted species are indicated by arrows. (c) Supershift assay using extracts from uninduced 32D c13 cells. Six micrograms of
nuclear extract was incubated with the oligonucleotide alone [32D (1L3)], with the addition of 1 [I of PEBP2/CBF antiserum (32D+Ab), with the
addition of antiserum and specific peptide (32D+Ab+pep), or with the addition of 1 ptl of normal rabbit serum (32D+RS)*, slowly migrating
doublet.
PU.1 (not shown), completely prevented the supershift of the
MyNF1 species. Addition of specific antiserum to the probe
alone, without nuclear extract, did not produce these super-
shift species (not shown). Since the N terminus of PEBP2aA is
nearly identical to that of PEBP2oB, with 15 (of 17) identities
and two conservative changes (4, 36), we conclude from these
experiments only that the MyNFIs are members of the PEBP2/
CBF family. Perhaps the unshifted MyNFlox contains a mod-
ified N terminus.
A similar supershift assay was also carried out with extracts
from uninduced 32D c13 cells (Fig. 3c). Again the MyNFlo and
MyNF1lB species were supershifted by the PEBP2otB anti-
serum, the specific peptide blocked this reaction, and normal
rabbit serum did not produce a supershift of the MyNFIs. Of
note, the more slowly migrating doublet observed with unin-
duced, but not induced, extracts (Fig. 1) did not supershift with
this antiserum, and neither did the minor species migrating just
above MyNFlo. We previously found that nuclear extracts
from SP2 lymphoid cells and MEL erythroid cells did not
contain the MyNFIs but did contain species which migrate
more slowly in a gel shift reaction with a PEBP2/CBF oligo-
nucleotide (47). These species also did not supershift with the
PEBP2otB N-terminus antiserum (not shown).
Cloning the murine NE promoter. To obtain the gene
encoding a second murine myeloid primary granule protein, we
screened a BALB/c lambda genomic library with the human
NE cDNA and obtained a clone with a 19-kb insert. The insert
was subcloned, and fragments containing exons were identified
by Southern blotting with the human NE cDNA as probe (not
shown). The five exons were sequenced in their entirety, along
with some neighboring DNA segments. The predicted amino
acid sequence of the mature murine NE protein is 81%
identical and 90% homologous to that of human NE. A search
of the GenBank and EMBL databases revealed that the
next-most-related protein-coding segment is that of human
azurocidin, another serine protease (2), which has 46% identity
and 56% homology.
To further verify the identity of the murine NE genomic
clone, mRNA was prepared from uninduced 32D c13 cells and
from cells induced with G-CSF for 4, 7, or 10 days. These
mRNAs were subjected to Northern blotting, and the filter was
probed sequentially for murine NE and for murine 15-tubulin
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FIG. 4. Northern blot analysis of murine NE and murine l5-
tubulin (Tub) expression in differentiating 32D c13 cells. Twenty
micrograms of total RNA from uninduced (1L3) or 4-, 7-, or 10-day-
induced (G4, G7, and GIO, respectively) 32D c13 cells were subjected
to Northern blotting and probed sequentially for these two mRNAs.
The position of 18S rRNA is indicated for each blot.
(Fig. 4). A 1.3-kb murine NE mRNA was observed in induced,
but not uninduced, 32D c13 cells. The human NE mRNA is
also 1.3 kb (49). The expression of murine NE mRNA de-
creases as 32D c13 cells mature from the promyelocyte stage
(day 4) to the neutrophil stage (day 10), as does the expression
of the two 35-tubulin mRNAs.
Finally, significant homologies in the human and murine NE
5'-flanking regions were also noted (Fig. 5). Within the first
100 bp, both the human and murine genes contain TATAA
homologies, as well as potential binding sites for members of
the Ets and C/EBP families and also for c-Myb. The murine
NE gene also contains an element, 5'-GGCCACA-3', which
differs from the PEBP2/CBF consensus, 5'-PuACCPuCA-3',
only by an A-to-G transition at the second position. The
element 5'-AGCCGCA-3', present in the enhancer core of
Pu.1
hNE: TTCATCAACGCCCTGTGCCAGGGGAGAGGAAGTGGAGGGC
mNE: GACACCCCCACTGTCGTGTC CCA(GGAGGAAGT AGGGC
-110 -100 -90 -80
PEBP2/CBF C/EBP c-Myb TATAA
GCTGGCCGGCCGTGGGGCAATGCAACGGCCTCCCCAGCACAGGGCTATAA
TGTGGCCAGGATGGGGCAATACAACGGCCTCTGGTTC CCAC CIATAA
-70 -60 -50 -40 -30
FIG. 5. Comparison of the murine NE and human NE 5'-flanking
regions. Both strands of the murine NE promoter were sequenced.
The sequences of the promoters of murine NE (mNE) and human NE
(hNE), upstream of the TATAA homologies, have been aligned.
Identities between these segments are underlined in the murine
sequence. Potential binding sites for PU.1, PEBP2/CBF, C/EBP,
c-Myb, and TATAA are indicated as well. Note that each of these
binding sites is conserved between murine NE and human NE, except
for the PEBP2/CBF site, which is disrupted in the human NE
promoter.
simian immunedeficiency virus, contains the same A-to-G
transition and has been shown to bind PEBP2/CBF (56).
The murine NE promoter contains several functional ele-
ments. A DNA fragment containing 1,800 bp of murine NE
5'-flanking sequences and the entire 5'-untranslated region
was linked upstream of the luciferase cDNA to create
pNELUC. In initial experiments we found that deletion of
pNELUC to position -1,000, -180, or -103 was of minimal
functional consequence (not shown). Clustered point muta-
tions were therefore introduced at six locations between
positions -107 and -42 in pNELUC. The activities of
pNELUC and of a 5'-deletion series of pNELUC with end-
points - 103, -91, -79, -66, -55, and -42 were assessed in
induced 32D c13 cells by transient transfection (Fig. 6a). The
activities of the six clustered point mutations in uninduced and
induced 32D c13 cells were evaluated (Fig. 6b).
Deletion to position -91 was of minimal consequence, and
mutation of bases -107 to -103 or -95 to -91 was of no
consequence, in induced 32D c13 cells. Additional deletion to
position -79, which removed a potential PU.1-binding site,
diminished NE promoter activity 10-fold (range, 9- to 23-fold),
and mutation of this site, in pNE(m-85/-79)LUC, decreased
activity 28-fold in induced 32D c13 cells. Further deletion to
position -66, which removed a potential PEBP2/CBF-binding
site, reduced NE promoter activity fivefold (range, four- to
sevenfold), and mutation of this site by altering bases -69 to
-66 resulted in threefold-lower activity. To verify that intro-
duction of an XhoI site at positions -69 to -66 had not
inadvertantly created a repressor-binding site, we used mung
bean nuclease to remove the central 4 bp of the XhoI site from
pNE(m-69/-66)LUC. The activity of this plasmid was also
threefold less than that of pNELUC in induced 32D c13 cells,
in each of three repetitions.
Deletion to position -55 removed a potential C/EBP-
binding element and decreased NE promoter activity an
additional sevenfold, although this finding, and the result of
further deletion to position -42, is difficult to evaluate because
the resulting luciferase activities approached background lev-
els. Disruption of the C/EBP-binding site with clustered mu-
tations at positions -61 to -55 decreased NE promoter
activity more than 30-fold, and disruption of the c-Myb site, in
pNE(-47/-42)LUC, decreased activity 5-fold. Thus, the con-
served segment of the murine NE 5'-flanking region contains
four functional elements.
Mutation of the PEBP2/CBF site increased pNELUC activ-
ity in L cells (one-, three-, or fivefold in three experiments).
Mutation of the murine MPO PEBP2/CBF site had no effect
on murine MPO proximal enhancer activity in L cells, and
MyNFIs were not detected in L-cell nuclear extracts (47).
Of note, pNELUC was 7-fold more active in induced,
compared with uninduced, 32D c13 cells, pNE(m-107/
-103)LUC was 11-fold induced, and pNE(m-95/-91)LUC
was 5-fold induced. However, the activity of pNE(m-61/
-55)LUC, which lacks a C/EBP site, was not induced by
G-CSF. The activities of pNE(m-85/-79)LUC, pNE(m-69/
-66)LUC, and pNE(m-47/-42)LUC increased two- to three-
fold. These data suggest that integrity of the C/EBP site is
critical for pNELUC induction and that integrity of the PU.1,
PEBP2/CBF, and c-Myb DNA elements is required for opti-
mal induction as well. Perhaps these four factors form a
complex on the promoter which stimulates binding of the basal
transcription machinery at the TATAA box. This model may
account for our observation that the contribution of each DNA
element to overall promoter function varied somewhat be-
tween experiments, increasing the standard errors for the
activities of some of the constructs.
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FIG. 6. Activity of murine NE (mNE) 5'-deletion and clustered point mutation constructs in 32D c13 cells. (a) Ten micrograms of each
diagrammed plasmids, containing 5' murine NE promoter deletions, was cotransfected with 0.5 ,ug of pMSVCAT into 32D c13 cells, which were
then cultured in the presence of G-CSF. Cell extracts were assayed for luciferase and CAT activities 2 days later. The ratio of luciferase to CAT
activities was set at 100% for pNELUC in each experiment. The average activity of each construct, in five experiments, is shown. Each average
is also shown numerically above each bar, along with the standard error in parentheses. (b) Fifteen micrograms of each diagrammed plasmid,
containing clustered point mutations introduced into the murine NE promoter segment in pNELUC, was cotransfected with 0.5 ,ug of pMSVCAT
into 32D c13 cells. These cultures were then split between interleukin 3- and G-CSF-containing media. Two days later, extracts were assayed for
luciferase and CAT activities. The activity of pNELUC in induced 32D c13 cells was set at 100% in each experiment. The average activity of each
construct, in at least four experiments, is shown.
The murine NE promoter element at positions -72 to -66
binds PEBP2/CBF. An oligonucleotide corresponding to bp
-81 to -57 of the murine NE promoter was prepared. This
oligonucleotide contains a centrally located, near-consensus
PEBP2/CBF site and includes a portion, but not all, of the
adjacent PU.1 and C/EBP sites. Similar oligonucleotides,
containing either a disrupted PEBP2/CBF element or a con-
sensus PEBP2/CBF site, were also prepared. These oligonu-
cleotides and a murine MPO-derived oligonucleotide contain-
ing a consensus PEBP2/CBF element were labelled to similar
specific activities and used in an EMSA with nuclear extracts
from 4-day-induced 32D c13 cells (Fig. 7a). The murine NE
oligonucleotide, but not the variant with a disrupted PEBP2/
CBF site, weakly bound both MyNF1ox and MyNF13, and no
other bands were evident. An additional oligonucleotide in
which the murine NE PEBP2/CBF site was disrupted by
introduction of an XhoI site, as was done for the functional
studies, also did not bind the MyNFls (not shown). Conversion
of the near-consensus PEBP2/CBF site to a consensus site, in
the context of the murine NE oligonucleotide, increased
binding of these factors to a level similar to that obtained with
the murine MPO oligonucleotide. Flanking sequences appear
not to influence the affinity of the MyNFls for the 7-bp
PEBP2/CBF site. To confirm these differences in affinity, an
EMSA competition experiment was performed (Fig. 7b). The
ability of a 10- or 50-fold excess of each unlabelled oligonu-
cleotide to compete for MyNFI binding to 1 ng of radiola-
belled murine NE oligonucleotide was determined. A 10-fold
excess of each of the three oligonucleotides with DNA ele-
ments which fit, or nearly fit, the PEBP2/CBF consensus
prevented binding almost completely, whereas even a 50-fold
excess of the mutant murine NE oligonucleotide only per-
turbed binding mildly.
The wild-type murine NE and MPO oligonucleotides were
employed in a supershift assay in the same experiment (Fig.
7c). Binding of MyNFl to either oligonucleotide was dis-
rupted or shifted completely, whereas binding of MyNFlox was
disrupted or shifted only partially, by inclusion of anti-PEBP2/
CBF ot subunit antiserum. A doublet containing these super-
shifted species was noted near the top of the gel. Finally, the
specific peptide again prevented interaction between the anti-
serum and the MyNFls.
b
100 (0)
46 (30)
71 (38)
7.1 (6.8)
1.5 (1.5)
0.2 (0.2)
0.3 (0.4)
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x
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FIG. 7. PEBP2/CBF binds the murine NE promoter. (a) Three murine NE-derived, 33-bp oligonucleotides were radiolabelled to similar
specific activities and used in an EMSA with 6 ,ug of 4-day-induced 32D c13 cell DFP nuclear extracts. The centrally located MyNFI-binding site
either was wild type (GGCCACAn), was mutant (GGTCTCGn), or matched the MyNFl-binding site in the murine MPO gene (AACCACAn).
The n in each of these designations indicates that the surrounding base pairs derive from the murine NE gene. A fourth oligonucleotide, containing
the murine MPO MyNFl-binding site and its neighboring sequences (AACCACAm), was assayed similarly. The positions of MyNF1Ix and
MyNF1B are indicated. (b) The wild-type murine NE oligonucleotide was radiolabelled and incubated with similar extracts either in the absence
of competitor (NC) or in the presence of either a 10- or 50-fold excess of each of the four unlabelled oligonucleotides described for panel a, here
designated NE-wt, NE-mut, NE-MPO, or MPO, respectively. (c) The wild-type murine NE or MPO oligonucleotides were radiolabelled, incubated
with 6 ,ug of 4-day-induced 32D c13 cell DFP nuclear extracts, and analyzed by EMSA (NE and MPO). The ability of an anti-PEBP2/CBF a subunit
antiserum to disrupt or supershift the MyNF1 species was assessed by adding 1 jil of antiserum to the nuclear extracts prior to probe addition
(NE+Ab or MPO+Ab). The specificity of the antiserum-MyNF1 interaction was assessed by addition of 4 ,ug of the specific peptide to the nuclear
extracts prior to antiserum addition (NE+Ab+pep or MPO+Ab+pep). The positions of supershifted species are indicated by arrows.
32D c13 cells contain both PEBP2aB and PEBP2aA
mRNAs. As discussed, the antiserum employed for the super-
shift assay would likely recognize both PEBP2aB and
PEBP2oA. We and others are attempting to obtain specific,
high-affinity antisera that will recognize these polypeptides. To
determine whether 32D c13 cells contain mRNAs encoding one
or both PEBP2ao, we prepared poly(A)+ mRNAs from unin-
duced, 3-day-induced, and 6-day-induced 32D c13 cells and
subjected these mRNAs to Northern blotting (Fig. 8).
PEBP2aB mRNAs of 6.2 and 2.1 kb were detected, as were
7.4- and 6.3-kb PEBP2otA mRNAs. These mRNAs correspond
in size to analogous mRNAs detected in other cell types (4,
36).
DISCUSSION
In a report of an initial investigation of the transcriptional
regulation of the murine MPO gene, we described a 414-bp
proximal enhancer (47). This enhancer contains several posi-
tively acting functional DNA elements. Mutation of one ele-
ment, 5'-AACCACA-3' was found to markedly diminish en-
hancer function, and the element was shown to bind a set of
myeloid-restricted factors, MyNFla and MyNF13. This DNA
element is also present at the analogous location in the human
MPO gene. Optimum function of the factor interacting with
this element depended on the presence of neighboring DNA-
binding elements (47). We have now demonstrated that the
MyNFls belong to the PEBP2/CBF family of transcription
factors. Mutation of this element to a site which still fit the
PEBP2/CBF consensus did not interfere with binding in vitro
or function in vivo, whereas mutation to a site which disrupted
the PEBP2/CBF consensus, but still fit the consensus for other
known viral enhancer core-binding proteins, abolished binding
in vitro and function in vivo. In vitro-translated PEBP2/CBF
DNA-binding domain bound this element. Also, PEBP2/CBF
at subunit-specific antiserum supershifted the MyNF1 com-
plexes. Thus, the MPO gene is the first identified myeloid gene
regulated by PEBP2/CBF.
To begin to determine whether PEBP2/CBF plays a general
role in regulating early myeloid maturation, we examined the
transcriptional regulation of the murine NE gene. The human
MPO and NE mRNAs are coordinately expressed in human
marrow (14). Striking conservation was noted within the
proximal 100 bp of the human and murine NE 5'-flanking
regions. Four DNA elements functional in induced 32D c13
cells were described. One of the elements is predicted to bind
a member of the Ets family. The Ets family member PU.1 has
been shown to regulate the CD11b and macrophage colony-
stimulating factor receptor genes in monocytes (37, 63), and it
may regulate the CD18 and CD11a genes as well (6, 44). The
murine NE PU.1 site fits the consensus sequence 5'-RRR
GAGGAAG-3' noted to be present in several genes expressed
in myeloid cells (44), although the active CDllb and macro-
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FIG. 8. Northern blot analysis of PEBP2aB, PEBP2aA, and tubu-
lin (Tub) expression in differentiating 32D cl3 cells. Five micrograms of
poly(A)+ RNA prepared from uninduced (IL3) or 3- or 6-day-induced
(G3 and G6, respectively) 32D c13 cells was subjected to Northern
blotting and probed sequentially for each of these mRNAs. Note that
each probe detected two isoforms of the corresponding mRNAs. The
positions of 28S and 18S rRNAs are indicated.
phage colony-stimulating factor receptor PU.1 sites differ from
this consensus (37, 63). The murine MPO proximal enhancer
contains this element as well, although its function has not
been evaluated by point mutation. The Ets family member
Ets-1 was recently shown to cooperatively bind DNA with
PEBP2/CBF, and there are functional Ets and PEBP2/CBF
sites in several viral enhancers (reference 61 and references
therein).
The functional murine NE C/EBP site fits the consensus
5'-T(T/G)NNGNAA(T/G)-3' (1). Interestingly, conservation
between the human and murine NE C/EBP sites extends
precisely over this 9-bp site. Of note, this site differs from the
CCAAT site known to bind ubiquitously expressed factors (7).
A C/EBP has been shown to cooperate with c-Myb to activate
the mim-1 and lysozyme genes in immature avian myeloid cells
(33), and a C/EBP activates the G-CSF gene in monocytes as
well (31). Interestingly, integrity of the C/EBP site was most
critical for increased pNELUC activity during 32D c13 cell
differentiation, and the levels of C/EBPa, C/EBP,B, and
C/EBP,y increase during early 32D c13 granulopoiesis (43).
Integrity of the segment 5'-CAACGG-3', which is present in
both the human and murine NE promoters and fits the c-Myb
consensus, 5'-(T/C)AAC(G/T)G-3' (5), is required for optimal
murine NE promoter function as well. The murine MPO gene
has an element 5'-CAACTG-3' just upstream of the PEBP2/
CBF-binding site, and mutation of this element decreased
murine MPO proximal enhancer function fivefold (47). The
corresponding segment of the human MPO gene has the
sequence 5'-TAACTG-3', which also fits the Myb consensus.
Integrity of adjacent c-Myb- and PEBP2/CBF-binding sites is
critical for activity of the TCR8 enhancer (16). Interestingly,
the murine MPO PEBP2/CBF site was able to stimulate a
hybrid murine MPO-TK promoter 20-fold in the absence of
the adjacent c-Myb site (47) (Fig. 2C), suggesting differences in
the makeups of the murine MPO and the TCR8 enhancers.
The murine, but not the human, NE promoter contains an
element, 5'-GGCCACA-3', which matches the PEBP2/CBF
consensus, 5'-PuACCPuCA-3', except for an A-to-G transition
at position 2. As previously described (56), we found that an
element with this transition will bind PEBP2/CBF, albeit
weakly compared with a consensus site. Mutation or removal
of the PEBP2/CBF element in the murine NE promoter
impaired promoter function approximately fourfold in induced
32D c13 myeloid cells. Thus, PEBP2/CBF binds and activates
the murine MPO proximal enhancer strongly (30-fold) and
binds and stimulates the analogous region of the murine NE
modestly. Also, PEBP2/CBF optimally activates both murine
MPO and NE only when neighboring cis-regulatory elements
are present.
The above discussion leads to the model that genes ex-
pressed specifically in immature myeloid cells are regulated by
some combination of a PEBP2/CBF, Myb or a Myb-related
protein, a C/EBP, and PU.1 or another Ets family member.
The contribution of each of these factors to regulating other
early myeloid genes, as well as more distal regions of the
murine and human NE genes, will need to be determined to
test this model. The mim-1 and lysozyme genes were activated
in nonmyeloid cells transfected with Myb and C/EBP expres-
sion vectors (33), and the macrophage colony-stimulating
factor receptor was activated by a PU.1 expression vector (63)
in nonmyeloid cells as well. We cotransfected pMPOHTKLUC
and pNELUC with expression vectors for PEBP2aB and
PEBP2I/CBFP in 32D c13 cells and in L cells. No consistent
trans-activation was found in either cell type. Presumably, L
cells require expression of additional myeloid activators to
allow MPO or NE enhancer function, and 32D c13 cells already
have abundant endogenous PEBP2/CBFs, preventing addi-
tional trans-activation. Experiments are in progress to identify
the additional factors which cooperate with PEBP2/CBFs to
regulate the murine MPO and NE proximal regulatory regions.
Perhaps we will then be able to identify a combination of these
regulators which is sufficient to activate both the MPO and NE
genes in nonmyeloid cells and which allows cooperative bind-
ing to enhancer fragments in vitro. Of note, both PEBP2cxA
and PEBP2aoB, the ao subunits of two PEBP2/CBF family
members, were recently shown to trans-activate a T-cell recep-
tor enhancer in two heterologous cell types containing reduced
levels of endogenous PEBP2/CBFs (3, 26a).
The distribution of PEBP2/CBF proteins in tissue has not
been established. PEBP2/CBF gel shift activities were detected
in extracts from myeloid and lymphoid cells but not in liver,
kidney, lung, or heart extracts (50, 56), although multiple cell
lines contain these activities (26, 47). We demonstrated that
32D c13 cells contain mRNAs corresponding to two PEBP2/
CBF at subunit family members, PEBP2aA and PEBP2aB.
Development of additional antiserum reagents will be neces-
sary to determine whether the two MyNF1 gel shift bands
contain one or both of these PEBP2/CBFs.
Finally, it is provocative that PEBP2/CBF regulates the
murine MPO and NE genes and that PEBP2/CBF subunit
genes are involved in translocations associated with myeloid
leukemias. A portion of the human PEBP2aB gene, the AML1
gene, is fused to the ETO gene by t(8;21), which is associated
with FAB M2 acute myeloid leukemia (12, 29). The marrows
of patients with this form of leukemia contain leukemic
myeloblasts, as well as more differentiated, MPO-positive,
leukemic cells. Thus, if AMLl-ETO blocks the differentiation
of some leukemic myeloblasts, this effect must be leaky. The
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PEBP2p/CBFP gene, encoding the common ,3 subunit of
PEBP2A and PEBP2B, is fused to the tail, coiled-coil region of
a smooth muscle myosin gene by inv(16), which is associated
with FAB M4eo cases of acute myeloid leukemia (24). The
marrows of these patients contain leukemic myeloblasts and
monoblasts, as well as leukemic eosinophils. It has been
proposed that the CBF,-MYH11 fusion protein produced by
inv(16) acts in a dominant-negative fashion with respect to
endogenous PEBP2/CBFs (24). The CBFP portion could bind
endogenous ot subunits, and the myosin portion could then
induce the formation of an inactive tetramer. Lack of PEBP2/
CBF functions might then prevent differentiation beyond the
blastic stage, much as interference of RARot function by the
PML-RARa oncogene, associated with FAB M3 cases of acute
myeloid leukemia, is thought to prevent differentiation of
myeloid cells beyond the promyelocyte stage of differentiation
(52). It will be of interest to determine the effect of AMLl-
ETO and CBFP-MYH11 on the endogenous MPO and NE
genes and on the MPO and NE gene reporter constructs we
have characterized. Since arrested differentiation might not be
sufficient to transform a normal myeloblast into a leukemic
cell, these oncogenes, and also PEBP2/CBF, might also affect
the expression of genes which regulate the proliferation of
myeloblasts.
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ADDENDUM IN PROOF
The MyNFls also supershifted with a CBFI3 antiserum provided by
N. Speck.
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